| 000 | 01706 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515105651.0 | ||
| 264 | 0 | _c20080724 | |
| 008 | 200807s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 024 | 7 |
_a10.1038/bmt.2008.2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGardner, S L | |
| 245 | 0 | 0 |
_aMyeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cMay 2008 |
||
| 300 |
_a867-72 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyeloablative Agonists _xtherapeutic use |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSarcoma, Ewing _xmortality |
| 650 | 0 | 4 |
_aStem Cell Transplantation _xmethods |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTransplantation, Autologous |
| 700 | 1 | _aCarreras, J | |
| 700 | 1 | _aBoudreau, C | |
| 700 | 1 | _aCamitta, B M | |
| 700 | 1 | _aAdams, R H | |
| 700 | 1 | _aChen, A R | |
| 700 | 1 | _aDavies, S M | |
| 700 | 1 | _aEdwards, J R | |
| 700 | 1 | _aGrovas, A C | |
| 700 | 1 | _aHale, G A | |
| 700 | 1 | _aLazarus, H M | |
| 700 | 1 | _aArora, M | |
| 700 | 1 | _aStiff, P J | |
| 700 | 1 | _aEapen, M | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 41 _gno. 10 _gp. 867-72 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/bmt.2008.2 _zAvailable from publisher's website |
| 999 |
_c17752165 _d17752165 |
||